PRAISE-U was initiated on the 1st of April 2023 and is set to last for three years. This collaborative effort involves 25 institutions across 12 countries, all driven by a shared objective: to rationalize prostate cancer screening in Europe and enhance patient outcomes. PRAISE-U advocates for EU member states to offer exceptional clinical standards, incorporating cutting-edge personalized approaches to enable timely detection of prostate cancer in individuals who can benefit from early treatment. To assess the functionality, feasibility, and long-term viability of a risk-based algorithm, the consortium will collaborate with pilot sites in Spain, Poland, Ireland, and Lithuania.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of clinically significant prostate cancer in each pilot site (with clinically significant prostate cancer defined as ISUP grade group ≥2).
Timeframe: 1 year
Invitation coverage
Timeframe: 1 year
Examination coverage
Timeframe: 1 year
Participation rate
Timeframe: 1 year
Retention rate
Timeframe: 1 year
Test result
Timeframe: 1 year
PPV of screening test to detect any prostate cancer (6.1) and clinically significant prostate cancers (6.2)
Timeframe: 1 year
PPV of screening test to detect any prostate cancer (6.1) and clinically significant prostate cancers (6.2)
Timeframe: 1 year
False positive rate to detect any PCa (7.1) and clinically significant PCa (7.2)
Timeframe: 1 year
False positive rate to detect any PCa (7.1) and clinically significant PCa (7.2)
Timeframe: 1 year
Compliance with risk assessment
Timeframe: 1 year
Compliance with further assessment
Timeframe: 1 year
Detection rate of PCa
Timeframe: 1 year
Compliance with treatment
Timeframe: 1 year
Complications in screening procedure
Timeframe: 1 year
Opportunistic testing
Timeframe: 1 year
Cause-specific mortality
Timeframe: 1 year
Crude Incidence rate
Timeframe: 1 year
Interval cancer rate
Timeframe: 1 year
Delay time
Timeframe: 1 year
Radiologist's assessment of MRI
Timeframe: 1 year
Compliance with biopsy
Timeframe: 1 year
Active surveillance
Timeframe: 1 year
Tumour grade distribution
Timeframe: 1 year